35309 COVID-19 outcomes among patients with cutaneous T-cell lymphoma: A multicentered analysis

Abstract

Background: As over 225 million cases of coronavirus-19 infection (COVID-19) have been reported to date worldwide with nearly 4.6 million deaths, the medical community is seeking to better understand the relationship between certain comorbidities and disease severity. Certain types of malignancies have been associated with worse COVID-19 outcomes. Here we assess the risk of severe COVID-19 disease in patients with pre-existing cutaneous T-cell lymphoma (CTCL) as it has yet to be investigated on a large-scale level. Design: TriNetX, a national research network of 75 million patients, was used in this retrospective study. Two cohorts of COVID-19 patients with and without a history of CTCL were selected using ICD-10 diagnosis codes and serology values of interest. Once constructed, 1:1 propensity score match (PSM) analysis was used to create two matched cohorts of patients controlled for demographics and comorbidities. Lastly, adjusted risk ratios with a 95% confidence interval was calculated for each measured 30-day outcome for mortality, hospitalization, need for mechanical ventilation, deep vein thrombosis (DVT), acute respiratory distress syndrome (ARDS), and sepsis. Summary: 260 COVID-19 patients with CTCL and 910,080 patients without CTCL were identified on TriNetX. After PSM, 2 balanced cohorts of 260 patients were compared with 1 another. Each group had a similar risk of each assessed outcome: mortality (aRR [95% CI]) = (1 [0.423,2362]), need for mechanical ventilation (1 [0.423,2.362]), hospitalization (1.2 [0.877,1.622]), ARDS (1 [0.423,2.362]), sepsis (1.7 [0.871,3.287]), and DVT (1 [0.423,2.362]). Conclusion: COVID-19 patients with a history of CTCL have similar risks of developing worse outcomes than those without a history of CTCL.